The Manufacturers Life Insurance Company Raises Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

The Manufacturers Life Insurance Company increased its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 28.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 102,037 shares of the company’s stock after buying an additional 22,337 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.19% of Vera Therapeutics worth $3,692,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of VERA. Public Employees Retirement Association of Colorado purchased a new stake in Vera Therapeutics in the 2nd quarter valued at approximately $135,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Vera Therapeutics in the 2nd quarter valued at about $163,000. Ameritas Investment Partners Inc. lifted its holdings in Vera Therapeutics by 20.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after purchasing an additional 688 shares in the last quarter. Cetera Advisors LLC acquired a new stake in shares of Vera Therapeutics during the 1st quarter worth about $235,000. Finally, Capstone Investment Advisors LLC purchased a new stake in shares of Vera Therapeutics during the first quarter worth about $248,000. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on VERA shares. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 target price on shares of Vera Therapeutics in a research report on Tuesday, October 1st. Evercore ISI raised Vera Therapeutics to a “strong-buy” rating in a research report on Monday, September 16th. Finally, JPMorgan Chase & Co. increased their target price on Vera Therapeutics from $62.00 to $72.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $51.75.

Vera Therapeutics Stock Down 2.0 %

Shares of NASDAQ VERA opened at $40.01 on Tuesday. The stock has a fifty day moving average price of $39.05 and a 200 day moving average price of $38.98. The company has a market cap of $2.19 billion, a P/E ratio of -20.09 and a beta of 1.00. Vera Therapeutics, Inc. has a 12-month low of $9.24 and a 12-month high of $50.78. The company has a current ratio of 21.43, a quick ratio of 21.43 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). Research analysts anticipate that Vera Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Insider Transactions at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 23,125 shares of the firm’s stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $46.05, for a total transaction of $1,064,906.25. Following the completion of the sale, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at approximately $14,182,110.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Vera Therapeutics news, CEO Marshall Fordyce sold 23,125 shares of the company’s stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $46.05, for a total value of $1,064,906.25. Following the completion of the transaction, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at $14,182,110.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Beth C. Seidenberg sold 1,177 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total value of $49,445.77. Following the sale, the director now owns 160,376 shares of the company’s stock, valued at $6,737,395.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 54,398 shares of company stock valued at $2,275,656. Corporate insiders own 21.70% of the company’s stock.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.